See the DrugPatentWatch profile for nivolumab

Based on the information available, there isn't a definitive answer regarding an optimal nivolumab dosage for maximum effectiveness. Nivolumab is a type of immunotherapy used to treat various types of cancer, and its dosage can vary depending on several factors, including the patient's weight, the type of cancer, and the stage of the disease.

According to the National Cancer Institute (NCI) [1], the typical dosage of nivolumab for most cancers is 240 milligrams (mg) every two weeks or 480 mg every four weeks until the disease progresses or the patient experiences unacceptable toxicity. However, the NCI also notes that the dosage may be adjusted based on the patient's kidney function, as well as any side effects or toxicities that occur during treatment.

Furthermore, a study published in the Journal of Clinical Oncology [2] found that there was no significant difference in overall survival or progression-free survival between patients who received a flat dose of 240 mg every two weeks and those who received a weight-based dose of 3 mg per kilogram every two weeks.

It's worth noting that the dosage of nivolumab can also be affected by patent restrictions. According to DrugPatentWatch.com [3], the patent for nivolumab (marketed under the brand name Opdivo) expired in the United States in October 2020, which may lead to the development of generic versions of the drug and potentially lower costs for patients. However, the expiration of the patent does not necessarily affect the recommended dosage or administration of the drug.

In summary, while there is a typical dosage range for nivolumab, there is no established optimal dosage for maximum effectiveness. The appropriate dosage may vary depending on the patient's individual circumstances and should be determined by a healthcare professional.

Sources:

1. National Cancer Institute. Nivolumab. <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>.
2. Brahmer J, Lacchetti C, Schneider BJ, et al. NCCN Guidelines Insights: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network. 2018;16(3):370-379. doi:10.6004/jnccn.2018.0012
3. DrugPatentWatch.com. Opdivo (nivolumab) Patent Expiration & Generics. <https://www.drugpatentwatch.com/patent/opdivo-nivolumab-patent-expiration-generics/>